News
The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of ...
On June 30, AbbVie announced its intention to acquire Capstan Therapeutics in a deal valued at up to $2.1 billion in cash.
Under terms of the deal, AbbVie will acquire Capstan’s lead asset, CPTX2309—an in vivo anti-CD19 CAR T-cell therapy in Phase ...
AbbVie has announced that it will be expanding its immunology capabilities by acquiring Capstan Therapeutics for up to $2.1bn ...
AbbVie Inc. (NYSE:ABBV) is one of the best high growth stocks. On June 30, Morgan Stanley maintained an Overweight rating and ...
AbbVie agreed to acquire Capstan Therapeutics, including its lead asset, for $2.1 billion in cash. The North Chicago, Ill., ...
AbbVie announced it will acquire Capstan Therapeutics, a startup developing CAR-T therapies for autoimmune conditions, ...
Capstan brings a new modality to AbbVie’s immunology pipeline. The most advanced Capstan program is CPTX2309, which is being developed as a treatment for B cell-mediated autoimmune disorders.
8d
Zacks.com on MSNWill AbbVie's Acquisition Spree Aid Pipeline Growth?ABBV's $2.1 billion Capstan deal and 20+ recent acquisitions sharpen its pipeline edge across immunology and beyond.
On June 30, AbbVie announced its intention to acquire Capstan Therapeutics in a deal valued at up to $2.1 billion in cash. The acquisition will expand AbbVie’s product pipeline, ...
AbbVie ABBV has been actively ramping up its deal-making efforts lately, ... The acquisition will also add Capstan’s proprietary tLNP platform technology, CellSeeker, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results